Sarepta Therapeutics (SRPT) Equity Average (2011 - 2026)

Sarepta Therapeutics has reported Equity Average for 16 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 0.93% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 0.93% YoY), and the FY2025 full-year result was $1.3 billion, up 11.78% from the prior year.
• Equity Average for Q1 2026 stood at $1.3 billion, up from $1.2 billion in the prior quarter.
• The five-year high for Equity Average was $1.4 billion in Q4 2024, with the low at $407.9 million in Q4 2022.
• Average Equity Average over 5 years is $967.1 million, with a median of $910.3 million recorded in 2024.
• Year-over-year, Equity Average sank 41.63% in 2022 and soared 99.03% in 2023.
• Tracing SRPT's Equity Average over 5 years: stood at $407.9 million in 2022, then surged by 99.03% to $811.8 million in 2023, then surged by 69.29% to $1.4 billion in 2024, then declined by 10.48% to $1.2 billion in 2025, then advanced by 7.52% to $1.3 billion in 2026.
• The last three Equity Average figures came in at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.

Peer Comparison